CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance

11/4/24 4:05:00 PM ET

$CDNA

Medical Specialities

Health Care

Get the next $CDNA alert in real time by email

CareDx, Inc. (NASDAQ:CDNA) – today announced financial results for the third quarter ended September 30, 2024.

Third Quarter 2024 Financial Highlights

Total revenue of $82.9 million increased 23% year-over-year
Testing Services volume of 44,600 tests increased 16% year-over-year
GAAP net loss of $7.4 million, non-GAAP net income of $8.0 million, and positive adjusted EBITDA of $6.9 million, a significant improvement from the third quarter 2023
Cash flow from operations of $12.5 million. Cash, cash equivalents, and marketable securities of $241 million, with no debt
Raised annual revenue guidance to $327 to $331 million and adjusted EBITDA to a gain of $18 to $22 million

Business Highlights

CMS reaffirmed longstanding Medicare coverage for AlloSure® and AlloMap® Testing
Surveillance testing mix in kidney began to increase in the second half of September and continued through October
Hired industry veterans Keith Kennedy, Chief Operating Officer; Jessica Meng, Chief Commercial Officer; and Jing Huang, PhD, Chief Data and AI Officer
Announced the launch of the next generation of Assign software for AlloSeq™ Tx HLA typing and enhancements to QTYPE® rapid typing solution for deceased donor HLA typing
DOJ concluded its investigation into CareDx with no finding of wrongdoing

"CareDx had another strong quarter of topline growth and achieved positive adjusted EBITDA for the second consecutive quarter. We raised our annual guidance, and remain focused on ending the year strong," said John W. Hanna, CareDx President and CEO.

Third Quarter 2024 Financial Results

Total revenue for the three months ended September 30, 2024, was $82.9 million, an increase of 23% compared to $67.2 million for the third quarter of 2023. Testing Services revenue for the third quarter 2024 was $60.8 million, an increase of 27% compared to $47.8 million for the third quarter of 2023. Testing Services revenue included $1.2 million for tests performed in prior periods. Patient and Digital Solutions revenue for the third quarter of 2024 was $11.9 million, an increase of 20% compared to $9.9 million for the third quarter 2023. Product revenue for the third quarter of 2024 was $10.2 million, an increase of 7% compared to $9.5 million for the third quarter 2023.

For the third quarter of 2024 net loss was $7.4 million compared to a net loss of $23.5 million in the third quarter of 2023. Basic and diluted net loss per share in the third quarter of 2024 was $0.14, compared to basic and diluted net loss per share of $0.43 in the third quarter of 2023.

Non-GAAP net income was $8.0 million in the third quarter of 2024, compared to a non-GAAP net loss of $9.6 million in the third quarter of 2023. Diluted non-GAAP net income per share was $0.14 in the third quarter of 2024, compared to a diluted non-GAAP net loss per share of $0.18 in the third quarter of 2023.

Adjusted EBITDA income for the third quarter of 2024 was $6.9 million, compared to an adjusted EBITDA loss of $10.9 million for the third quarter of 2023.

2024 Guidance

CareDx now expects full year 2024 revenue to be in the range of $327 million to $331 million, compared to the prior guidance of $320 million to $328 million. CareDx now expects full year 2024 non-GAAP gross margin to be approximately 69%, compared to the prior range of 67% to 68%. CareDx now expects full year 2024 adjusted EBITDA gain to be in the range of $18 million to $22 million, compared to the prior guidance of an adjusted EBITDA gain of $9 million to $15 million.

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Forward Looking Statements

This press release includes forward-looking statements, including expectations regarding CareDx's 2024 revenue, and non-GAAP gross margin and adjusted EBITDA. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, all of which are difficult to predict and many of which are beyond our control, including general economic and market factors, among others discussed in CareDx's filings with the Securities and Exchange Commission (the "SEC"), including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by CareDx with the SEC on February 28, 2024, the quarterly report on Form 10-Q for the quarter ended March 31, 2024 filed by CareDx with the SEC on May 9, 2024, the quarterly report on Form 10-Q for the quarter ended June 30, 2024 filed by CareDx with the SEC on July 31, 2024, the quarterly report on Form 10-Q for the quarter ended September 30, 2024 filed by CareDx with the SEC on November 4, 2024, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx's actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Use of Non-GAAP Financial Measures

CareDx has presented in this release certain financial information in accordance with U.S. Generally Accepted Accounting Principles ("GAAP") and also on a non-GAAP basis, including non-GAAP cost of testing services, non-GAAP cost of product, non-GAAP cost of patient and digital solutions, non-GAAP research and development expenses, non-GAAP sales and marketing expenses, non-GAAP general and administrative expenses, non-GAAP other income, net, non-GAAP income tax expense, non-GAAP gross profit, non-GAAP gross margin (%), non-GAAP net income (loss), non-GAAP basic and diluted net income (loss) per share, adjusted EBITDA and non-GAAP operating expenses.

We define non-GAAP net income (loss) and per share results as the GAAP net loss and per share results excluding the impacts of stock-based compensation; changes in estimated fair value of contingent consideration; acquisition-related impairment charges and amortization of purchased intangible assets and related tax effects; costs involved with completing an acquisition; unrealized loss on investments; restructuring charges and certain other charges.

We define adjusted EBITDA as non-GAAP net income (loss) before interest income, income tax expense (benefit), depreciation and other (income) expense, net. We are presenting these non-GAAP financial measures to assist investors in assessing our operating results through the eyes of management and because we believe that these measures provide an additional tool for investors to use in comparing our core business operating results over multiple periods. Management believes this non-GAAP information is useful for investors, when considered in conjunction with CareDx's GAAP financial statements, because management uses such information internally for its operating, budgeting, and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of CareDx's operating results as reported under GAAP. These non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. These non-GAAP financial measures are not necessarily comparable to similarly titled measures presented by other companies. A reconciliation between GAAP and non-GAAP financial information is provided immediately following the financial tables.

CareDx, Inc. Condensed Consolidated Statements of Operations (Unaudited) (In thousands, except share and per share data)

	Three Months Ended September 30,						Nine Months Ended September 30,
		2024			2023			2024			2023
Revenue:
Testing services revenue	$	60,807		$	47,784		$	185,562		$	162,982
Product revenue		10,212			9,536			29,416			24,273
Patient and digital solutions revenue		11,864			9,872			32,228			27,500
Total revenue		82,883			67,192			247,206			214,755
Operating expenses:
Cost of testing services		13,447			13,217			41,387			43,837
Cost of product		6,212			4,750			17,801			12,742
Cost of patient and digital solutions		7,913			6,566			22,264			19,807
Research and development		17,486			19,000			55,875			63,590
Sales and marketing		19,802			18,474			60,634			63,335
General and administrative		28,515			33,968			83,104			91,327
Restructuring costs		—			—			68			848
Total operating expenses		93,375			95,975			281,133			295,486
Loss from operations		(10,492	)		(28,783	)		(33,927	)		(80,731	)
Other income:
Interest income, net		3,001			3,171			8,712			8,708
Change in estimated fair value of common stock warrant liability		—			—			—			10
Other income (expense), net		283			2,047			(107	)		(198	)
Total other income		3,284			5,218			8,605			8,520
Loss before income taxes		(7,208	)		(23,565	)		(25,322	)		(72,211	)
Income tax (expense) benefit		(200	)		80			(139	)		24
Net loss	$	(7,408	)	$	(23,485	)	$	(25,461	)	$	(72,187	)
Net loss per share:
Basic	$	(0.14	)	$	(0.43	)	$	(0.49	)	$	(1.34	)
Diluted	$	(0.14	)	$	(0.43	)	$	(0.49	)	$	(1.34	)
Weighted-average shares used to compute net loss per share:
Basic		52,903,338			54,178,759			52,266,106			53,891,374
Diluted		52,903,338			54,178,759			52,266,106			53,891,374


CareDx, Inc. Condensed Consolidated Balance Sheets (Unaudited) (In thousands)

	September 30, 2024			December 31, 2023
Assets
Current assets:
Cash and cash equivalents	$	95,400		$	82,197
Marketable securities		145,453			153,221
Accounts receivable		66,627			51,061
Inventory		19,263			19,471
Prepaid and other current assets		7,344			7,763
Total current assets		334,087			313,713
Property and equipment, net		34,015			35,246
Operating leases right-of-use assets		25,823			29,891
Intangible assets, net		40,361			45,701
Goodwill		40,336			40,336
Restricted cash		592			586
Other assets		1,771			1,353
Total assets	$	476,985		$	466,826
Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$	6,239		$	12,872
Accrued compensation		29,915			19,703
Accrued and other liabilities		45,286			45,497
Total current liabilities		81,440			78,072
Deferred tax liability		202			136
Deferred payments for intangible assets		1,310			2,461
Operating lease liability, less current portion		23,841			28,278
Other liabilities		96,946			96,551
Total liabilities		203,739			205,498
Commitments and contingencies
Stockholders' equity:
Common stock		50			49
Additional paid-in capital		984,627			946,511
Accumulated other comprehensive loss		(7,179	)		(6,963	)
Accumulated deficit		(704,252	)		(678,269	)
Total stockholders' equity		273,246			261,328
Total liabilities and stockholders' equity	$	476,985		$	466,826


CareDx, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) (In thousands)

	Three Months Ended September 30,						Nine Months Ended September 30,
		2024			2023			2024			2023
Cost of testing services reconciliation:
GAAP cost of testing services	$	13,447		$	13,217		$	41,387		$	43,837
Stock-based compensation expense		(418	)		(496	)		(1,232	)		(1,467	)
Acquisition related-amortization of purchased intangibles		(329	)		(329	)		(987	)		(987	)
Non-GAAP cost of testing services	$	12,700		$	12,392		$	39,168		$	41,383
Cost of product reconciliation:
GAAP cost of product	$	6,212		$	4,750		$	17,854		$	12,742
Stock-based compensation expense		(234	)		(301	)		(776	)		(935	)
Acquisition related-amortization of purchased intangibles		(419	)		(408	)		(1,250	)		(1,242	)
Restructuring costs		—			—			(53	)		—
Non-GAAP cost of product	$	5,559		$	4,041		$	15,775		$	10,565
Cost of patient and digital solutions reconciliation:
GAAP cost of patient and digital solutions	$	7,913		$	6,566		$	22,264		$	19,821
Stock-based compensation expense		(326	)		(297	)		(1,048	)		(1,066	)
Acquisition related-amortization of purchased intangibles		(170	)		(265	)		(679	)		(768	)
Restructuring costs		—			—			—			(14	)
Other income		—			—			5			—
Non-GAAP cost of patient and digital solutions	$	7,417		$	6,004		$	20,542		$	17,973
Research and development expenses reconciliation:
GAAP research and development expenses	$	17,486		$	19,000		$	55,890		$	63,835
Stock-based compensation expense		(1,775	)		(1,491	)		(5,163	)		(5,157	)
Restructuring costs		—			—			(15	)		(245	)
Other charges		—			—			(25	)		—
Non-GAAP research and development expenses	$	15,711		$	17,509		$	50,687		$	58,433
Sales and marketing expenses reconciliation:
GAAP sales and marketing expenses	$	19,802		$	18,474		$	60,634		$	63,883
Stock-based compensation expense		(2,786	)		(3,041	)		(8,757	)		(9,557	)
Acquisition related-amortization of purchased intangibles		(634	)		(616	)		(1,895	)		(1,817	)
Restructuring costs		—			—			—			(548	)
Other charges		—			—			(8	)		—
Non-GAAP sales and marketing expenses	$	16,382		$	14,817		$	49,974		$	51,961
General and administrative expenses reconciliation:
GAAP general and administrative expenses	$	28,515		$	33,968		$	83,104		$	91,368
Stock-based compensation expense		(8,155	)		(7,045	)		(23,232	)		(20,943	)
Change in estimated fair value of contingent consideration		(232	)		(1,243	)		(761	)		(1,731	)
Acquisition related fees and expenses		—			(253	)		(40	)		(537	)
Restructuring costs and charges		—			—			—			(41	)
Other (charges) income		—			(6	)		22			(64	)
Non-GAAP general and administrative expenses	$	20,128		$	25,421		$	59,093		$	68,052
Total other income (expense) reconciliation:
GAAP other income, net	$	3,284		$	5,218		$	8,605		$	8,520
Unrealized gain on long-term marketable equity securities		—			333			—			1,190
Asset impairments and write-downs		—			—			—			1,000
Other charges		—			(2,109	)		—			(2,081	)
Non-GAAP other income, net	$	3,284		$	3,442		$	8,605		$	8,629
Income tax (expense) benefit reconciliation:
GAAP income tax (expense) benefit	$	(200	)	$	80		$	(139	)	$	24
Tax effect related to amortization of purchased intangibles		(102	)		(98	)		(302	)		(299	)
Non-GAAP income tax expense	$	(302	)	$	(18	)	$	(441	)	$	(275	)


CareDx, Inc. GAAP and Non-GAAP Operating Expenses (Unaudited) (In thousands)

	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
GAAP operating expenses:
Research and development	$	17,486	$	19,000	$	55,890	$	63,835
Sales and marketing		19,802		18,474		60,634		63,883
General and administrative		28,515		33,968		83,104		91,368
Total GAAP operating expenses	$	65,803	$	71,442	$	199,628	$	219,086

Non-GAAP operating expenses:
Research and development	$	15,711	$	17,509	$	50,687	$	58,433
Sales and marketing		16,382		14,817		49,974		51,961
General and administrative		20,128		25,421		59,093		68,052
Total Non-GAAP operating expenses	$	52,221	$	57,747	$	159,754	$	178,446


CareDx, Inc. Reconciliation of GAAP to Non-GAAP Gross Profit and Gross Margin (Unaudited) (In thousands, except percentages)

	Three Months Ended September 30,						Nine Months Ended September 30,
		2024			2023			2024			2023
Total revenue	$	82,883		$	67,192		$	247,206		$	214,755
GAAP cost of sales		27,572			24,533			81,505			76,400
GAAP gross profit		55,311			42,659			165,701			138,355
Stock-based compensation expense		978			1,094			3,056			3,468
Other income		—			—			(5	)		—
Restructuring costs		—			—			53			14
Acquisition related-amortization of purchased intangibles		918			1,002			2,916			2,997
Non-GAAP gross profit	$	57,207		$	44,755		$	171,721		$	144,834
Non-GAAP gross margin %		69	%		67	%		69	%		67	%


CareDx, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) (In thousands, except share and per share data)

	Three Months Ended September 30,						Nine Months Ended September 30,
		2024			2023			2024			2023
GAAP net loss	$	(7,408	)	$	(23,485	)	$	(25,461	)	$	(72,187	)
Stock-based compensation expense		13,694			12,671			40,208			39,125
Acquisition related-amortization of purchased intangibles		1,552			1,618			4,811			4,814
Change in estimated fair value of contingent consideration		232			1,243			761			1,731
Acquisition related fees and expenses		—			253			40			537
Other (gains) charges		—			(2,109	)		6			(2,081	)
Restructuring costs and charges		—			6			68			912
Tax effect related to amortization of purchased intangibles		(102	)		(98	)		(302	)		(299	)
Asset impairments and write-downs		—			—			—			1,000
Unrealized loss on long-term marketable equity securities		—			333			—			1,190
Non-GAAP net income (loss)	$	7,968		$	(9,568	)	$	20,131		$	(25,258	)

GAAP basic and diluted net loss per share	$	(0.14	)	$	(0.43	)	$	(0.49	)	$	(1.34	)

Non-GAAP basic net income (loss) per share	$	0.15		$	(0.18	)	$	0.39		$	(0.47	)
Non-GAAP diluted net income (loss) per share	$	0.14		$	(0.18	)	$	0.36		$	(0.47	)

Shares used in computing non-GAAP basic net income (loss) per share		52,903,338			54,178,759			52,266,106			53,891,374
Shares used in computing non-GAAP diluted net income (loss) per share		57,699,624			54,178,759			55,609,263			53,891,374


CareDx, Inc. Reconciliation of Non-GAAP to Adjusted EBITDA (Unaudited) (In thousands)

	Three Months Ended September 30,						Nine Months Ended September 30,
		2024			2023			2024			2023
Non-GAAP net income (loss)	$	7,968		$	(9,568	)	$	20,131		$	(25,258	)
Interest income		(3,001	)		(3,171	)		(8,712	)		(8,708	)
Income tax expense (benefit)		302			(214	)		441			275
Depreciation expense		1,919			2,044			6,024			5,904
Other (income) expense, net		(283	)		(40	)		107			79
Adjusted EBITDA	$	6,905		$	(10,949	)	$	17,991		$	(27,708	)

View source version on businesswire.com: https://www.businesswire.com/news/home/20241104115097/en/

Get the next $CDNA alert in real time by email

Recent Analyst Ratings for

$CDNA

Date	Price Target	Rating	Analyst
1/6/2026	$26.00	Buy → Hold	Craig Hallum
8/26/2025		Mkt Perform	William Blair
1/15/2025	$28.00 → $24.00	Underweight → Equal Weight	Wells Fargo
8/28/2024	$28.00	Underweight	Wells Fargo
8/19/2024	$40.00	Neutral → Buy	BTIG Research
5/13/2024		Outperform → Mkt Perform	Raymond James
5/1/2024	$15.00	Hold → Buy	Craig Hallum
11/9/2023	$10.00	Equal-Weight → Overweight	Stephens

More analyst ratings

CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance

11/4/24 4:05:00 PM ET

$CDNA

Medical Specialities

Health Care

Get the next $CDNA alert in real time by email

CareDx, Inc. (NASDAQ:CDNA) – today announced financial results for the third quarter ended September 30, 2024.

Third Quarter 2024 Financial Highlights

Total revenue of $82.9 million increased 23% year-over-year
Testing Services volume of 44,600 tests increased 16% year-over-year
GAAP net loss of $7.4 million, non-GAAP net income of $8.0 million, and positive adjusted EBITDA of $6.9 million, a significant improvement from the third quarter 2023
Cash flow from operations of $12.5 million. Cash, cash equivalents, and marketable securities of $241 million, with no debt
Raised annual revenue guidance to $327 to $331 million and adjusted EBITDA to a gain of $18 to $22 million

Business Highlights

CMS reaffirmed longstanding Medicare coverage for AlloSure® and AlloMap® Testing
Surveillance testing mix in kidney began to increase in the second half of September and continued through October
Hired industry veterans Keith Kennedy, Chief Operating Officer; Jessica Meng, Chief Commercial Officer; and Jing Huang, PhD, Chief Data and AI Officer
Announced the launch of the next generation of Assign software for AlloSeq™ Tx HLA typing and enhancements to QTYPE® rapid typing solution for deceased donor HLA typing
DOJ concluded its investigation into CareDx with no finding of wrongdoing

Third Quarter 2024 Financial Results

Adjusted EBITDA income for the third quarter of 2024 was $6.9 million, compared to an adjusted EBITDA loss of $10.9 million for the third quarter of 2023.

2024 Guidance

About CareDx – The Transplant Company

Forward Looking Statements

Use of Non-GAAP Financial Measures

CareDx, Inc. Condensed Consolidated Statements of Operations (Unaudited) (In thousands, except share and per share data)

	Three Months Ended September 30,						Nine Months Ended September 30,
		2024			2023			2024			2023
Revenue:
Testing services revenue	$	60,807		$	47,784		$	185,562		$	162,982
Product revenue		10,212			9,536			29,416			24,273
Patient and digital solutions revenue		11,864			9,872			32,228			27,500
Total revenue		82,883			67,192			247,206			214,755
Operating expenses:
Cost of testing services		13,447			13,217			41,387			43,837
Cost of product		6,212			4,750			17,801			12,742
Cost of patient and digital solutions		7,913			6,566			22,264			19,807
Research and development		17,486			19,000			55,875			63,590
Sales and marketing		19,802			18,474			60,634			63,335
General and administrative		28,515			33,968			83,104			91,327
Restructuring costs		—			—			68			848
Total operating expenses		93,375			95,975			281,133			295,486
Loss from operations		(10,492	)		(28,783	)		(33,927	)		(80,731	)
Other income:
Interest income, net		3,001			3,171			8,712			8,708
Change in estimated fair value of common stock warrant liability		—			—			—			10
Other income (expense), net		283			2,047			(107	)		(198	)
Total other income		3,284			5,218			8,605			8,520
Loss before income taxes		(7,208	)		(23,565	)		(25,322	)		(72,211	)
Income tax (expense) benefit		(200	)		80			(139	)		24
Net loss	$	(7,408	)	$	(23,485	)	$	(25,461	)	$	(72,187	)
Net loss per share:
Basic	$	(0.14	)	$	(0.43	)	$	(0.49	)	$	(1.34	)
Diluted	$	(0.14	)	$	(0.43	)	$	(0.49	)	$	(1.34	)
Weighted-average shares used to compute net loss per share:
Basic		52,903,338			54,178,759			52,266,106			53,891,374
Diluted		52,903,338			54,178,759			52,266,106			53,891,374


CareDx, Inc. Condensed Consolidated Balance Sheets (Unaudited) (In thousands)

	September 30, 2024			December 31, 2023
Assets
Current assets:
Cash and cash equivalents	$	95,400		$	82,197
Marketable securities		145,453			153,221
Accounts receivable		66,627			51,061
Inventory		19,263			19,471
Prepaid and other current assets		7,344			7,763
Total current assets		334,087			313,713
Property and equipment, net		34,015			35,246
Operating leases right-of-use assets		25,823			29,891
Intangible assets, net		40,361			45,701
Goodwill		40,336			40,336
Restricted cash		592			586
Other assets		1,771			1,353
Total assets	$	476,985		$	466,826
Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$	6,239		$	12,872
Accrued compensation		29,915			19,703
Accrued and other liabilities		45,286			45,497
Total current liabilities		81,440			78,072
Deferred tax liability		202			136
Deferred payments for intangible assets		1,310			2,461
Operating lease liability, less current portion		23,841			28,278
Other liabilities		96,946			96,551
Total liabilities		203,739			205,498
Commitments and contingencies
Stockholders' equity:
Common stock		50			49
Additional paid-in capital		984,627			946,511
Accumulated other comprehensive loss		(7,179	)		(6,963	)
Accumulated deficit		(704,252	)		(678,269	)
Total stockholders' equity		273,246			261,328
Total liabilities and stockholders' equity	$	476,985		$	466,826


CareDx, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) (In thousands)

	Three Months Ended September 30,						Nine Months Ended September 30,
		2024			2023			2024			2023
Cost of testing services reconciliation:
GAAP cost of testing services	$	13,447		$	13,217		$	41,387		$	43,837
Stock-based compensation expense		(418	)		(496	)		(1,232	)		(1,467	)
Acquisition related-amortization of purchased intangibles		(329	)		(329	)		(987	)		(987	)
Non-GAAP cost of testing services	$	12,700		$	12,392		$	39,168		$	41,383
Cost of product reconciliation:
GAAP cost of product	$	6,212		$	4,750		$	17,854		$	12,742
Stock-based compensation expense		(234	)		(301	)		(776	)		(935	)
Acquisition related-amortization of purchased intangibles		(419	)		(408	)		(1,250	)		(1,242	)
Restructuring costs		—			—			(53	)		—
Non-GAAP cost of product	$	5,559		$	4,041		$	15,775		$	10,565
Cost of patient and digital solutions reconciliation:
GAAP cost of patient and digital solutions	$	7,913		$	6,566		$	22,264		$	19,821
Stock-based compensation expense		(326	)		(297	)		(1,048	)		(1,066	)
Acquisition related-amortization of purchased intangibles		(170	)		(265	)		(679	)		(768	)
Restructuring costs		—			—			—			(14	)
Other income		—			—			5			—
Non-GAAP cost of patient and digital solutions	$	7,417		$	6,004		$	20,542		$	17,973
Research and development expenses reconciliation:
GAAP research and development expenses	$	17,486		$	19,000		$	55,890		$	63,835
Stock-based compensation expense		(1,775	)		(1,491	)		(5,163	)		(5,157	)
Restructuring costs		—			—			(15	)		(245	)
Other charges		—			—			(25	)		—
Non-GAAP research and development expenses	$	15,711		$	17,509		$	50,687		$	58,433
Sales and marketing expenses reconciliation:
GAAP sales and marketing expenses	$	19,802		$	18,474		$	60,634		$	63,883
Stock-based compensation expense		(2,786	)		(3,041	)		(8,757	)		(9,557	)
Acquisition related-amortization of purchased intangibles		(634	)		(616	)		(1,895	)		(1,817	)
Restructuring costs		—			—			—			(548	)
Other charges		—			—			(8	)		—
Non-GAAP sales and marketing expenses	$	16,382		$	14,817		$	49,974		$	51,961
General and administrative expenses reconciliation:
GAAP general and administrative expenses	$	28,515		$	33,968		$	83,104		$	91,368
Stock-based compensation expense		(8,155	)		(7,045	)		(23,232	)		(20,943	)
Change in estimated fair value of contingent consideration		(232	)		(1,243	)		(761	)		(1,731	)
Acquisition related fees and expenses		—			(253	)		(40	)		(537	)
Restructuring costs and charges		—			—			—			(41	)
Other (charges) income		—			(6	)		22			(64	)
Non-GAAP general and administrative expenses	$	20,128		$	25,421		$	59,093		$	68,052
Total other income (expense) reconciliation:
GAAP other income, net	$	3,284		$	5,218		$	8,605		$	8,520
Unrealized gain on long-term marketable equity securities		—			333			—			1,190
Asset impairments and write-downs		—			—			—			1,000
Other charges		—			(2,109	)		—			(2,081	)
Non-GAAP other income, net	$	3,284		$	3,442		$	8,605		$	8,629
Income tax (expense) benefit reconciliation:
GAAP income tax (expense) benefit	$	(200	)	$	80		$	(139	)	$	24
Tax effect related to amortization of purchased intangibles		(102	)		(98	)		(302	)		(299	)
Non-GAAP income tax expense	$	(302	)	$	(18	)	$	(441	)	$	(275	)


CareDx, Inc. GAAP and Non-GAAP Operating Expenses (Unaudited) (In thousands)

	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
GAAP operating expenses:
Research and development	$	17,486	$	19,000	$	55,890	$	63,835
Sales and marketing		19,802		18,474		60,634		63,883
General and administrative		28,515		33,968		83,104		91,368
Total GAAP operating expenses	$	65,803	$	71,442	$	199,628	$	219,086

Non-GAAP operating expenses:
Research and development	$	15,711	$	17,509	$	50,687	$	58,433
Sales and marketing		16,382		14,817		49,974		51,961
General and administrative		20,128		25,421		59,093		68,052
Total Non-GAAP operating expenses	$	52,221	$	57,747	$	159,754	$	178,446


CareDx, Inc. Reconciliation of GAAP to Non-GAAP Gross Profit and Gross Margin (Unaudited) (In thousands, except percentages)

	Three Months Ended September 30,						Nine Months Ended September 30,
		2024			2023			2024			2023
Total revenue	$	82,883		$	67,192		$	247,206		$	214,755
GAAP cost of sales		27,572			24,533			81,505			76,400
GAAP gross profit		55,311			42,659			165,701			138,355
Stock-based compensation expense		978			1,094			3,056			3,468
Other income		—			—			(5	)		—
Restructuring costs		—			—			53			14
Acquisition related-amortization of purchased intangibles		918			1,002			2,916			2,997
Non-GAAP gross profit	$	57,207		$	44,755		$	171,721		$	144,834
Non-GAAP gross margin %		69	%		67	%		69	%		67	%


CareDx, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) (In thousands, except share and per share data)

	Three Months Ended September 30,						Nine Months Ended September 30,
		2024			2023			2024			2023
GAAP net loss	$	(7,408	)	$	(23,485	)	$	(25,461	)	$	(72,187	)
Stock-based compensation expense		13,694			12,671			40,208			39,125
Acquisition related-amortization of purchased intangibles		1,552			1,618			4,811			4,814
Change in estimated fair value of contingent consideration		232			1,243			761			1,731
Acquisition related fees and expenses		—			253			40			537
Other (gains) charges		—			(2,109	)		6			(2,081	)
Restructuring costs and charges		—			6			68			912
Tax effect related to amortization of purchased intangibles		(102	)		(98	)		(302	)		(299	)
Asset impairments and write-downs		—			—			—			1,000
Unrealized loss on long-term marketable equity securities		—			333			—			1,190
Non-GAAP net income (loss)	$	7,968		$	(9,568	)	$	20,131		$	(25,258	)

GAAP basic and diluted net loss per share	$	(0.14	)	$	(0.43	)	$	(0.49	)	$	(1.34	)

Non-GAAP basic net income (loss) per share	$	0.15		$	(0.18	)	$	0.39		$	(0.47	)
Non-GAAP diluted net income (loss) per share	$	0.14		$	(0.18	)	$	0.36		$	(0.47	)

Shares used in computing non-GAAP basic net income (loss) per share		52,903,338			54,178,759			52,266,106			53,891,374
Shares used in computing non-GAAP diluted net income (loss) per share		57,699,624			54,178,759			55,609,263			53,891,374


CareDx, Inc. Reconciliation of Non-GAAP to Adjusted EBITDA (Unaudited) (In thousands)

	Three Months Ended September 30,						Nine Months Ended September 30,
		2024			2023			2024			2023
Non-GAAP net income (loss)	$	7,968		$	(9,568	)	$	20,131		$	(25,258	)
Interest income		(3,001	)		(3,171	)		(8,712	)		(8,708	)
Income tax expense (benefit)		302			(214	)		441			275
Depreciation expense		1,919			2,044			6,024			5,904
Other (income) expense, net		(283	)		(40	)		107			79
Adjusted EBITDA	$	6,905		$	(10,949	)	$	17,991		$	(27,708	)

View source version on businesswire.com: https://www.businesswire.com/news/home/20241104115097/en/

Get the next $CDNA alert in real time by email

Recent Analyst Ratings for

$CDNA

Date	Price Target	Rating	Analyst
1/6/2026	$26.00	Buy → Hold	Craig Hallum
8/26/2025		Mkt Perform	William Blair
1/15/2025	$28.00 → $24.00	Underweight → Equal Weight	Wells Fargo
8/28/2024	$28.00	Underweight	Wells Fargo
8/19/2024	$40.00	Neutral → Buy	BTIG Research
5/13/2024		Outperform → Mkt Perform	Raymond James
5/1/2024	$15.00	Hold → Buy	Craig Hallum
11/9/2023	$10.00	Equal-Weight → Overweight	Stephens

More analyst ratings

CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$CDNA

CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$CDNA

$CDNA
Insider Trading

Chief Operating Officer Kennedy Keith was granted 74,474 shares and covered exercise/tax liability with 4,644 shares, increasing direct ownership by 50% to 209,139 units (SEC Form 4)

Chief Commercial Officer Meng Jessica covered exercise/tax liability with 4,430 shares and was granted 71,579 shares, increasing direct ownership by 61% to 176,778 units (SEC Form 4)

Chief Financial Officer Smith Nathan was granted 40,875 shares and covered exercise/tax liability with 3,859 shares, increasing direct ownership by 88% to 79,016 units (SEC Form 4)

$CDNA
Press Releases

CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference

CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy

CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

$CDNA
Analyst Ratings

CareDx downgraded by Craig Hallum with a new price target

William Blair initiated coverage on CareDx

CareDx upgraded by Wells Fargo with a new price target

$CDNA
SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by CareDx Inc.

SEC Form SCHEDULE 13G filed by CareDx Inc.

SEC Form 144 filed by CareDx Inc.

$CDNA
Leadership Updates

CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer

CareDx Announces Appointment of Suresh Gunasekaran to Board of Directors

CareDx Announces Appointment of Nathan Smith as Chief Financial Officer

$CDNA
Financials

CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings

CareDx to Report Third Quarter 2025 Financial Results on November 4, 2025

$CDNA
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by CareDx Inc.

Amendment: SEC Form SC 13G/A filed by CareDx Inc.

Amendment: SEC Form SC 13G/A filed by CareDx Inc.

CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $CDNA

CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $CDNA

$CDNA Insider Trading

Chief Operating Officer Kennedy Keith was granted 74,474 shares and covered exercise/tax liability with 4,644 shares, increasing direct ownership by 50% to 209,139 units (SEC Form 4)

Chief Commercial Officer Meng Jessica covered exercise/tax liability with 4,430 shares and was granted 71,579 shares, increasing direct ownership by 61% to 176,778 units (SEC Form 4)

Chief Financial Officer Smith Nathan was granted 40,875 shares and covered exercise/tax liability with 3,859 shares, increasing direct ownership by 88% to 79,016 units (SEC Form 4)

$CDNA Press Releases

CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference

CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy

CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

$CDNA Analyst Ratings

CareDx downgraded by Craig Hallum with a new price target

William Blair initiated coverage on CareDx

CareDx upgraded by Wells Fargo with a new price target

$CDNA SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by CareDx Inc.

SEC Form SCHEDULE 13G filed by CareDx Inc.

SEC Form 144 filed by CareDx Inc.

$CDNA Leadership Updates

CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer

CareDx Announces Appointment of Suresh Gunasekaran to Board of Directors

CareDx Announces Appointment of Nathan Smith as Chief Financial Officer

$CDNA Financials

CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings

CareDx to Report Third Quarter 2025 Financial Results on November 4, 2025

$CDNA Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by CareDx Inc.

Amendment: SEC Form SC 13G/A filed by CareDx Inc.

Amendment: SEC Form SC 13G/A filed by CareDx Inc.

Recent Analyst Ratings for
$CDNA

Recent Analyst Ratings for
$CDNA

$CDNA
Insider Trading

$CDNA
Press Releases

$CDNA
Analyst Ratings

$CDNA
SEC Filings

$CDNA
Leadership Updates

$CDNA
Financials

$CDNA
Large Ownership Changes